Stocks and Investing
Stocks and Investing
Tue, June 27, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Raghuram Selvaraju Reiterated (VRNA) at Strong Buy and Held Target at $32 on, Jun 27th, 2023
Raghuram Selvaraju of HC Wainwright & Co., Reiterated "Verona Pharma plc" (VRNA) at Strong Buy and Held Target at $32 on, Jun 27th, 2023.
Raghuram has made no other calls on VRNA in the last 4 months.
There are 2 other peers that have a rating on VRNA. Out of the 2 peers that are also analyzing VRNA, 0 agree with Raghuram's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Raghuram
- Edward Nash of "Canaccord Genuity" Maintained at Sell with Increased Target to $33 on, Wednesday, May 10th, 2023
- Thomas Shrader of "BTIG" Maintained at Strong Buy with Increased Target to $31 on, Monday, March 20th, 2023
Contributing Sources